Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

TYRA vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANNX Captures Overall Composite Edge (43.5 HOLD vs 34.0 SELL), While TYRA Leads 3–1 on Growth & Valuation Pillars

ANNX Overall Winner 6-Pillar Tally: TYRA 3 – 1 ANNX (2 Tie) Matrix Metrics: TYRA 3 – 1 ANNX

As of Nov 17, 2026, Annexon, Inc. (ANNX) captures the overall head-to-head institutional edge over Tyra Biosciences, Inc. (TYRA) on higher Unified Composite conviction (43.5/100 HOLD vs. 34.0/100 SELL) after splitting the core matrix 1–3 (led by Options & Positioning), while TYRA wins 3–1 across the 6-pillar growth and valuation breakdown. TYRA trades at $19.57 (N/M Forward P/E, 0.0% operating margin) versus ANNX at $3.47 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ANNX earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. TYRA 34.0/100 SELL) and 1.70β · 63% Vol risk profile, whereas TYRA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TYRA vs ANNX
TYRA NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.57
-0.86% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.79β · 48% Vol
Unified Composite Score
34.0 / 100 SELL
Tech 30.0 Fund 48.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 40
RSI-14: 40.3 · SMA20: $20.89 · SMA50: $21.43
ANNX NASDAQ Head-to-Head Winner
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.47
-2.8% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (TYRA 3 – 1 ANNX)

Columns: Metric · TYRA · ANNX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TYRA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.4B $747.8M
3. Profitability & Quality TYRA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -34.9% -130.8%
4. Balance Sheet & Cash Flow TYRA
Cash Generation (TTM) -$120M -$190M
Cash Flow Margin N/A N/A
Net Cash / Leverage $451M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 69.0% (3rd %ile) 569.3% (100th %ile)
Put/Call OI Skew 5.00x (Put-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TYRA (3) vs ANNX (1)
Institutional Metric TYRA ANNX Criterion Row Edge
Market Capitalization
Scale
$1.4B $747.8M Larger Scale TYRA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-34.9% -130.8% Higher ROE TYRA
52-Week Range Position
Momentum
18% ($15–$41) 18% ($3–$7) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.79β · 48% Vol 1.70β · 63% Vol Lower Realized Risk TYRA
Unified Institutional Score
Composite Signal
34.0 / 100 (SELL) 43.5 / 100 (HOLD) Higher Composite ANNX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$120M ($451M Net Cash) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TYRA +14.66 pp
TYRA: +1.19% · ANNX: -13.47%
3M Horizon TYRA +9.91 pp
TYRA: -27.0% · ANNX: -36.91%
6M Horizon ANNX +12.74 pp
TYRA: -42.07% · ANNX: -29.33%
1Y Horizon ANNX +3.63 pp
TYRA: +24.41% · ANNX: +28.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TYRA vs ANNX. Trailing 12-month operating profitability (TYRA 0.0% vs ANNX 0.0%) and valuation multiples (TYRA N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TYRA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.9% · N/M
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TYRA BREAKDOWN
77d in phase · OBV DISTRIBUTION
Current IV 69.0%
IV Percentile 3rd %ile
Put/Call OI Skew 5.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TYRA vs ANNX Key Questions & Quantitative Answers

As of Nov 17, 2026, Annexon, Inc. (ANNX) captures the overall head-to-head institutional edge over Tyra Biosciences, Inc. (TYRA) on higher Unified Composite conviction (43.5/100 HOLD vs. 34.0/100 SELL) after splitting the core matrix 1–3 (led by Options & Positioning), while TYRA wins 3–1 across the 6-pillar growth and valuation breakdown. TYRA trades at $19.57 (N/M Forward P/E, 0.0% operating margin) versus ANNX at $3.47 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ANNX earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. TYRA 34.0/100 SELL) and 1.70β · 63% Vol risk profile, whereas TYRA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TYRA leads the Growth & Scale pillar: TYRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TYRA generates N/A in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, TYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

TYRA and ANNX trade at balanced relative valuation multiples. TYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TYRA (-34.9% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, TYRA carries 69.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 5.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.79β · 48% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.